← Back to Search

Stem Cell Mobilizer

MGTA-145 for Acute Myeloid Leukemia

Phase 2
Waitlist Available
Research Sponsored by Ensoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 21, 28, 56, 100, 180, and 365
Awards & highlights

Summary

This research study tests a new medicine for mobilizing stem cells so they can be collected and used for allogeneic stem cell transplant for treatment of hematological malignancies. MGTA-145, the new medicine, will be given with plerixafor.

Eligible Conditions
  • Peripheral Blood Stem Cell Donation
  • Healthy Donors
  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Myelodysplastic Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 21, 28, 56, 100, 180, and 365
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 21, 28, 56, 100, 180, and 365 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Adverse Events Experienced by Donors
Adverse Events Related to Allograft
Graft Durability
+7 more

Side effects data

From 2022 Phase 2 trial • 25 Patients • NCT04552743
52%
Pain
28%
Paresthesia
24%
Nausea
20%
Platelet count decreased
20%
Hypocalcemia
12%
Anemia
12%
Hypokalemia
8%
Vomiting
8%
Headache
8%
Oral dysesthesia
4%
Other - Poor Graft Function (anemia, neutropenia, thrombocytopenia)
4%
Diarrhea
4%
Constipation
4%
Aspartate aminotransferase increased
4%
Alanine aminotransferase increased
4%
Dizziness
4%
Hot flashes
4%
Insomnia
4%
Urinary frequency
4%
Hyperhidrosis
4%
Fatigue
4%
Chills
100%
80%
60%
40%
20%
0%
Study treatment Arm
MGTA-145 and Plerixafor HSC Mobilization

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single dose MGTA-145 plus plerixafor followed by apheresisExperimental Treatment2 Interventions
MGTA-145 in combination with plerixafor followed by apheresis on one or two consecutive days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Plerixafor
2011
Completed Phase 3
~710
MGTA-145
2019
Completed Phase 2
~160

Find a Location

Who is running the clinical trial?

EnsomaLead Sponsor
3 Previous Clinical Trials
131 Total Patients Enrolled
Magenta Therapeutics, Inc.Lead Sponsor
6 Previous Clinical Trials
164 Total Patients Enrolled
National Marrow Donor ProgramOTHER
60 Previous Clinical Trials
202,553 Total Patients Enrolled
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top